- Home
- IGI vs CLYM Comparison
IGI vs CLYM Comparison
Compare IGI & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGI
- CLYM
- Stock Information
- Founded
- IGI 2009
- CLYM 2018
- Country
- IGI United States
- CLYM United States
- Employees
- IGI N/A
- CLYM N/A
- Industry
- IGI Investment Managers
- CLYM
- Sector
- IGI Finance
- CLYM
- Exchange
- IGI Nasdaq
- CLYM NYSE
- Market Cap
- IGI 99.2M
- CLYM 101.6M
- IPO Year
- IGI N/A
- CLYM 2021
- Fundamental
- Price
- IGI $16.55
- CLYM $1.28
- Analyst Decision
- IGI
- CLYM
- Analyst Count
- IGI 0
- CLYM 0
- Target Price
- IGI N/A
- CLYM N/A
- AVG Volume (30 Days)
- IGI 33.9K
- CLYM 183.8K
- Earning Date
- IGI 01-01-0001
- CLYM 03-25-2025
- Dividend Yield
- IGI 4.79%
- CLYM N/A
- EPS Growth
- IGI N/A
- CLYM N/A
- EPS
- IGI N/A
- CLYM N/A
- Revenue
- IGI N/A
- CLYM N/A
- Revenue This Year
- IGI N/A
- CLYM N/A
- Revenue Next Year
- IGI N/A
- CLYM N/A
- P/E Ratio
- IGI N/A
- CLYM N/A
- Revenue Growth
- IGI N/A
- CLYM N/A
- 52 Week Low
- IGI $15.13
- CLYM $1.20
- 52 Week High
- IGI $17.79
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- IGI 46.92
- CLYM N/A
- Support Level
- IGI $16.48
- CLYM N/A
- Resistance Level
- IGI $16.62
- CLYM N/A
- Average True Range (ATR)
- IGI 0.18
- CLYM 0.00
- MACD
- IGI -0.01
- CLYM 0.00
- Stochastic Oscillator
- IGI 20.00
- CLYM 0.00
About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.